The mechanisms regulating tumor cell dissemination in locally advanced squamous cell carcinoma of the head and neck region (SCCHN) are largely unresolved. We assessed the frequency of circulating tumor cells (CTCs), their association with clinicopathologic parameters and their kinetics during radiochemotherapy.
introduction A significant improvement in the locoregional control of squamous cell carcinoma of the head and neck region (SCCHN) has been achieved over the last decades by the introduction of new surgical approaches and chemoradiotherapy [1] [2] [3] or bioradiation protocols [4] . Though the improvement in the clinical management significantly increased survival rates, the latter are still offset by a significant number of distant failures [2] . Clinicopathologic characteristics such as tumor site, local (T stage) and regional (N stage) extension and histological grade have been shown to significantly influence the occurrence of distant metastases in SCCHN [5, 6] . The molecular mechanisms regulating such tumor cell dissemination, however, still remain largely elusive.
Presumably, distant metastases are the result of hematogenous dissemination of tumor cells. Indeed, circulating epithelial cells in the peripheral blood of patients with solid epithelial tumors including breast [7, 8] , colorectal [9, 10] and prostate cancers [11, 12] have been associated with increased risk of local or distant metastases. A few studies using either RT-PCR-assisted detection of epithelial-cell-specific messenger RNA (mRNA) transcripts [13] [14] [15] [16] [17] or immunocytochemical detection of cells expressing epithelial cell markers [17, 18] revealed the presence of circulating epithelial cells, supposedly derived from the primary tumor, also in peripheral blood samples of SCCHN patients. The study with the largest patient cohort in this series included 36 patients with operable SCCHN and revealed a significant association between positive RT-PCR and distant metastasis-free and overall survival (OS) [17] .
The previously applied techniques for detection of circulating tumor cells (CTCs) in SCCHN did not allow their detailed phenotypic characterization, which would help in the identification of potential molecular targets for the prevention or treatment of distant disease. In the present study, a flow cytometric assay for the detection and phenotypic characterization of CTCs was developed and independently validated using nested RT-PCR analysis of epidermal growth factor receptor (EGFR) transcripts [19] . Both protocols were then applied to assess the correlation of CTCs with clinicopathologic parameters and the influence of definitive chemoradiation on their detection rate.
methods and materials patients and controls
This study was approved by the local ethics committee. After informed patient consent, 42 consecutive unselected patients with histologically confirmed locally advanced inoperable SCCHN presenting at our clinical department for treatment were included in this study. Clinicopathologic characteristics of these patients are presented in Table 1 . Staging was carried out according to the TNM (tumor-node-metastasis) classification system. At the time point of the first blood sampling, none of the patients had started definitive chemoradiation.
volumetric measurements
Delineation and volumetric measurements of the primary tumor and the affected lymph nodes (gross tumor volume) were done on all axial computed tomography slices, with a slice thickness of 3.75 mm, using the Eclipse Treatment Planning Software (version 8.6; Varian, Palo Alto, CA) or the iPlan RT Image 4.1 Software (BrainLAB AG, Feldkirchen, Germany).
detection of CTCs by flow cytometry
After discarding the first 2.5 ml of blood to avoid potential contamination with skin epithelial cells, peripheral blood samples (7.5 ml) were collected into heparinized tubes (BD Biosciences Europe, Heidelberg, Germany). Samples were stored at room temperature until further processing within 24 h after blood sampling. After lysis of erythrocytes, CTCs were enriched by depletion of the CD45+ leukocyte fraction using a magnetic bead separation technique (EasySepÒ; Stem Cells Technologies, Inc., Grenoble, France) according to the manufacturer's instructions. The remaining cell suspension was split into two fractions each then containing a 3.75 ml aliquot of the peripheral blood sample. These two aliquots were stained with either a cocktail of specific antibodies to epithelial cell adhesion molecule (EpCAM) (clone EBA-1, allophycocyanin labeled; BD Biosciences), pan-cytokeratin (clone C-11, fluorescein isothiocyanate labeled; Sigma-Aldrich GmbH, Munich, Germany) and CD45 (clone HI30, phycoerythrin Cyä7 labeled; BD Biosciences) or the relevant isotype control antibodies (BD Biosciences). Using flow cytometry (FACSCanto II; BD Biosciences), CTCs defined as EpCAM+cytokeratin+CD452 were detected. A blood sample was considered CTC+ when at least one EpCAM+cytokeratin+CD452 cell was detected. The absolute numbers of CTCs per 3.75 ml blood were determined by recording all events in the 3.75 ml aliquot.
detection of circulating EGFR transcripts by nested RT-PCR
As an independent method for detection of CTCs, we used detection of EGFR transcripts by nested RT-PCR as biomarker for CTCs [19, 20] . For this analysis, 36 of 42 cases were available. Processing of blood samples for mRNA analysis was carried out as described previously [21, 22] . Briefly, a 7.5 ml aliquot of blood was centrifuged and the plasma was removed. The remaining cell suspension was mixed with 5 ml of 4 M guanidine isothiocyanate buffer and stored at 280°C until RNA extraction. Total cellular RNA was extracted using a guanidine isothiocyanate-phenolchloroform procedure together with Phase Lock Gel Heavyä tubes (5 Prime, Hamburg, Germany) and the High-Pure RNA isolation kit (Roche Diagnostics, Mannheim, Germany). Synthesis of complementary DNA (cDNA) (was carried out with 'Omniscript kit' (Qiagen GmbH, Hilden, Germany), according to the supplied protocol, using random hexamers and oligo dT15 primers (Roche) and 2 lg of total RNA. The quality of RNA was checked by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) PCR and only samples positive for GAPDH transcripts were used for EGFR-nested RT-PCR. In the first-round PCR, we used the forward primer 1: 5#-CTTCTTGCAGCGATACAGCTC-3# and the reverse primer 1: 5#-ATGCTCCAATAAATTCACTGC-3# [20] . These primers amplify a 440-bp fragment of the EGFR cDNA. The nested PCR was carried out by using the forward primer 2: 5#-CCCCACAGGCGCCTTGACTG-3# and the reverse primer 2: 5#-TGCTTTGTGGCGCGACCCTT-3# and the PCR product was 398 bp in length. PCR was carried out in a reaction volume of 25 ll containing 2 ll cDNA, 2.5 ll 10· PCR buffer, 2.5 mM MgCl 2 , 500 nM of each primer, the four deoxynucleoside triphosphates (200 nM each) and 1 unit of InviTaq DNA polymerase (Invitek GmbH, Berlin, Germany).
PCR cycling was carried out on a MastercyclerÒ thermal cycler (Eppendorf, Hamburg, Germany). After initial denaturation at 95°C for 5 min, the reaction was carried out at 95°C denaturation for 1 min, 60°C annealing for 30 s, and 72°C elongation for 1 min for 30 cycles. The extension was lengthened to 5 min during the last cycle. First-round PCR product of 2.5 ll was used for the subsequent nested PCR, which was carried out using the same cycling conditions but with 35 cycles in total.
Ten microliters of the PCR product was electrophoresed through a 1.5 % NuSieveÒ agarose gel. The gel was stained with Sybr GreenÒ (Sigma, Lonza, Rockland, ME) for visualization of DNA. Nested RT-PCR was carried out in triplicates and samples regarded as positive if at least one of the triplicates was positive.
immunohistochemical analysis of p16 INK4A expression
For the evaluation of p16 INK4A expression in tumor tissue as surrogate marker for human papillomavirus (HPV) positivity, tissue microarrays (TMAs) were generated using a precision instrument (Beecher Instruments, Silver Spring, MD). From each tissue specimen, hematoxylin-and eosinstained sections were generated and tumor areas marked by an experienced pathologist. Two tissue cylinders of 1 mm diameter were punched from each tumor-bearing donor block and were transferred to the recipient TMA block.
Immunohistochemistry was carried out on 3-lm formalin-fixed paraffinembedded tissue sections of the TMA using a Dako autostainer (Dako, Copenhagen, Denmark). Antigen retrieval was carried out by boiling slides in buffer containing 6.5 mM sodium citrate (pH = 6.0) in a sealed pressure cooker for 10 min. After antigen retrieval, sections were incubated with mouse-anti-p16
INK4A antibody (BD Biosciences, clone G175-405, dilution 1 : 50). Detection was carried out using the EnVision+ system HRP antimouse (Dako) with the 3-3#-diaminobenzidine chromogen (Dako). Slides were counterstained with hematoxylin, dehydrated and mounted. Omission of the primary antibody was used as a negative control. Tumors were classified as either p16 INK4A positive (defined as strong diffuse nuclear and cytoplasmic staining in >10% of carcinoma cells [23] ) or negative.
statistical analysis
The association of CTC+ cases (defined by ‡1 CTCs per 3.75 ml blood or a specific product in the nested RT-PCR reaction) with clinical parameters or p16 INK4A positivity was assessed using Fisher's exact test. This test was also used to correlate the results from CTC detection by flow cytometry and RT-PCR. For multivariate analysis with the presence of CTCs as the dependent variable, logistic regression was carried out. The level of significance was set at P < 0.05. Statistical analyses were carried out using the Statview software (version 5.0.1; SAS Institute Inc., Cary, NC).
results flow cytometric detection of CTCs
For detection of CTCs in peripheral blood of SCCHN patients, we used expression of EpCAM and cytokeratin since both markers have been proven suitable for the detection of single SCCHN cells in previous studies [14, 24] . For optimization of the protocol for immunomagnetic enrichment and flow cytometric detection of EpCAM+cytokeratin+ CTCs, we carried out spiking experiments. As a model for CTCs in spiking experiments we used the epithelial colorectal cancer cell line SW620 since phenotypic characterization of all epithelial cell line models available in our laboratory revealed for this cell line the most uniform expression pattern of EpCAM and of those types of cytokeratins recognized by the cytokeratin-specific antibody clone C-11. In the tested range from 5 to 500, SW620 cells spiked into 5 ml blood EpCAM+cytokeratin+ cells could be detected in all spiked samples. The detection rate was linear (R 2 = 0.998; Figure 1A ), with a mean recovery rate of 64%, ranging from 40% to 90%.
For establishment of nested RT-PCR-spiking experiments using in this case, the SCCHN cell line, UD-4, as a model for EGFR+ CTCs were carried out, which revealed a comparable sensitivity for the nested RT-PCR protocol: down to 5 UD-4 cells spiked into 10 ml whole blood from a healthy donor could be detected ( Figure 1B) .
Analysis of peripheral blood samples from 30 healthy donors revealed comparable specificity for flow cytometry and nested RT-PCR with a high correlation between both methods: 4 of 30 samples were positive by flow cytometry and 3 of these 4 samples tested also positive in the nested RT-PCR.
detection of CTCs in peripheral blood of inoperable SCCHN patients
Both methods were then applied for detection of CTCs in peripheral blood samples from SCCHN patients. Representative CTC+ SCCHN cases identified by flow cytometry or by nested RT-PCR are presented in Figure 1C and D, respectively. The flow cytometric analysis of peripheral blood samples from 42 SCCHN patients with nonresectable locally advanced disease presenting at our department for definitive chemoradiation revealed presence of CTCs in 18 of 42 SCCHN cases (43%, Figure 2A ). The mean number of CTCs 6 standard deviation detected in the CTC+ cases was 1.7 6 0.9 cells per 3.75 ml blood, ranging from 1 to 4 cells.
Detection of CTCs by nested RT-PCR for EGFR which could be carried out for 36 of 42 cases revealed significant correlation between CTC detection by flow cytometry and nested RT-PCR ( Figure 2B ).
correlation of CTC detection with T stage and tumor volume
We first asked whether the presence of CTCs was associated with the size of the tumor and stratified patients according to their T stage. As shown in Figure 3A , the clinical T stage was neither associated with the absolute numbers of CTCs per 3.75 ml blood (T0-T3 versus T4, Fisher's exact P value = 0.23) nor the frequency of CTC+ cases (P > 0.999). Since the T stage not only reflects tumor size but also its invasiveness into surrounding tissue, we also determined the total tumor volume and stratified patients into two cohorts using the median tumor volume as a cut-off. No significant association between the tumor volume and the absolute numbers of CTCs (P = 0.23) nor their frequency (P = 0.35) was observed ( Figure 3B ).
correlation of CTC detection with locoregional metastasis
We next assessed whether the presence of CTCs was correlated with lymph node metastasis. We grouped patients according to their N stage and compared the frequency of CTC+ cases in these groups. Although CTC+ cases were also observed in the N0/N1 stage patient group, their frequency was significantly increased in patients with N stage 2b or higher ( Figure 4A ). Indeed, 4 CTC+ cases of 19 cases (21%) could be observed in the N0-N2a group as compared with 14 CTC+ cases of 23 cases (61%) in the N2b+ group (P = 0.013, Figure 4A ). This significant correlation between regional metastasis and presence original article Annals of Oncology of CTCs could be also observed when analysis was carried out by nested RT-PCR (P = 0.017, Figure 4B ).
We then carried out a logistic regression analysis in which we included T stage, N stage and tumor volume. As presented in Table 2 , this analysis revealed that the association between the presence of CTCs, either detected by flow cytometry (Table 2A) or nested RT-PCR (Table 2B ) and the N stage remained significant in the multivariate regression model.
interference of tumor localization and HPV status with CTC detection
We then assessed whether the frequency of CTC detection was influenced by the primary tumor site. As presented in Table 3 , we observed the highest incidence of CTC+ cases among patients in whom the tumor was located in the oral cavity followed by the patient subgroup with oropharyngeal cancer. Since an increasing prevalence of HPV-associated cases has recently been reported mainly for these two sites and since HPV-associated SCCHN has to be regarded as a biologically distinct entity with significantly improved outcome, we wondered whether the frequency of CTC detection was dependent on the HPV status. As surrogate marker for HPV, we used immunohistochemical analysis of HPVassociated p16
INK4A expression. The overall frequency of p16
INK4A
-positive cases in our cohort was 38%, with the 
influence of chemoradiation on CTC numbers
In order to evaluate whether chemoradiation can target tumor cells with a presumed metastatic potential, the influence of treatment on the frequency of CTCs was assessed in 23 patients. Sequential samples collected before initiation of treatment and at an early time point (<4 weeks after therapy start) were available for 23 patients. An additional sample at a late point of treatment ( ‡4 weeks after start) was available for 10 patients. Patients received hyperfractionated accelerated radiotherapy (HART) combined with either 5-fluorouracil (5-FU)/cisplatin (N = 13), cisplatin (N = 5) or 5-FU/mitomycin C (N = 5). We observed a significant reduction in the frequency of detectable CTCs from 47% (prior treatment) to 16% during the first 4 weeks of treatment, which did not decrease further when CTC analysis was carried out at a later time point ( Figure 5A) . A comparable result was obtained when CTCs were detected by nested RT-PCR for EGFR ( Figure 5B ). Persistence of CTC may reflect failure to control disease dissemination, but since the time points for sample collection varied, the observed persistence of CTCs might also reflect the treatment dose delivered. However, a comparison of the numbers of radiotherapy applications/chemotherapy cycles between CTC2 and CTC+ cases ( Figure 5 , lower panel) did not reveal any significant differences excluding this factor as potential bias.
discussion
During the last century, the overall incidence of distant metastases in SCCHN has been reported to be <10% [25, 26] , which however, increased to up to 60% if presence of metastases was assessed during autopsy [27] . With the continuous improvement of the local control rate by current treatment modalities together with advances in the imaging techniques for diagnostic workup [28] , the number of SCCHN patients diagnosed and treated for metastatic disease has significantly increased [28] [29] [30] . Since curative treatment of metastatic disease is currently not successful and likewise life expectancy of these patients is poor, a better understanding of the mechanisms involved in tumor cell dissemination is urgently needed.
CTCs may represent the key reservoir for development of metachronous metastasis as has been shown in a variety of neoplasms. Moreover, recent findings indicate an additional role for CTCs as they seem to be able to efficiently re-seed into the initial tumor tissue [31] , thereby probably contributing not only to distant but also to locoregional recurrence as well. Using two independent methods for detection of commonly used epithelial tumor cell-associated markers, we identified CTCs in a large proportion of patients with nonmetastatic SCCHN. Our study confirms previous RT-PCR-based studies in SCCHN [13, 17, 32] and also shows the validity of our flow cytometry-based detection, which will be a prerequisite for molecular characterization of CTCs on a single-cell level.
Specificity of nested RT-PCR for detection of EGFR transcripts was high. However, in 10% of healthy controls, circulating EGFR transcripts could be detected. Interestingly, for all these cases positive in the nested EGFR RT-PCR, we also detected EpCAM+cytokeratin+EGFR+ cells by flow cytometry, indicating that under some yet undefined circumstances epithelial cells can circulate in peripheral blood of nontumor patients as well. Strategies to improve the specificity of CTC detection in future studies will investigate direct visualization and more specific molecular markers. original article
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The absolute numbers of CTCs per 3.75 ml blood detected in our study were low. This is in line with the very low CTC counts reported for other tumor models such as nonmetastatic breast cancer. Indeed, CTC analysis using the CellSearchÒ system in a large cohort of Her2+ patients revealed the presence of CTCs in 22% of patients with 50% of them showing 1 CTC per 7.5 ml and only 20% having >5 CTCs per 7.5 ml blood [33] .
The size of the CTC pool was not simply a function of tumor burden with larger tumors seeding more cells into the circulation than smaller ones. Our results suggest that tumors of CTC+ cases have distinct pathological characteristics endowing them to migrate from the primary site to regional lymph nodes and likely to distant organs as well. Future studies will have to address whether there a continuum of CTC incidence from N0-N1 to N2-N3 as well as whether the observed correlation between CTC detection and tumor localization can be confirmed in larger patient cohorts. Previous studies support our hypothesis that the presence of CTCs might predict the development of distant metastases in SCCHN. Indeed, the N stage that was significantly CTC, circulating tumor cell; SCCHN, squamous cell carcinoma of the head and neck region; CI, confidence interval. 
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correlated with the detection of CTCs in our study and by trend in the previous study of Partridge et al. [17] was one of the strongest prognosticators of distant metastasis-free survival [25, 26, 29, 34, 35] . These data suggest that detection of CTCs might represent a novel noninvasive diagnostic tool for predicting the occurrence of metastatic disease in SCCHN. Though CTC could be detected more frequently in patients with N2b or higher, there were also CTC+ cases without clinically detectable lymph node metastasis. Therefore, the presence of CTCs may provide prognostic information in addition to the clinical N stage, a question to be addressed with longer follow-up of our patient cohort and within the framework of prospective clinical trials. Besides prognostic information of baseline CTC numbers, the analysis of their kinetics over time might provide additional relevant information since persistence of CTCs under treatment could allow the early identification of nonadequate treatment modalities and nonresponding tumors. Indeed, a significant correlation between treatment-related changes in CTC numbers or their persistence after treatment with progression-free survival and OS in metastatic colorectal [9] and prostate cancer [36] and with relapse-free survival in nonmetastatic breast cancer [37] has been demonstrated. Of note, therapy-related changes in CTC numbers provided additional prognostic information when combined with radiographic imaging in colorectal cancer [9] and had higher prognostic power than assessment of changes in prostate-specific antigen titers in prostate cancer [36] .
In our study of nonresectable SCCHN, we observed a reduction in the frequency of CTC+ cases during the course of chemoradiation already at an early time point at which chemotherapy had not yet started. This implies a direct inhibitory effect of radiotherapy alone on the migration of tumor cells to the peripheral blood. No further reduction in CTCs was apparent at later time points when three cycles of chemotherapy on average have been given. This result was not unexpected since addition of concomitant chemotherapy to radiotherapy though reducing the risk of locoregional recurrence only slightly reduced the risk of distant failure [38] . However, patient numbers were limited and treatment conditions slightly different in our study, which leaves the prognostic potential of CTCs persisting chemoradiation to be resolved by future therapy trials including larger cohorts of patients. The analysis of CTCs using the flow cytometric approach established here seems feasible within the setting of multicenter trials since blood samples can processed after storage for up to 48 h without significant loss of sensitivity and specificity. Indeed, using the single-cell based CellSearchÒ system, the successful integration of CTC enumeration in prospective multicenter clinical trials of breast cancer has already been demonstrated [33, 39] . We have therefore integrated the analysis of CTCs before and after treatment in an ongoing multicenter randomized phase II clinical trial of inoperable SCCHN in which the efficacy of docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by bioradiation will be compared with standard chemoradiation.
In conclusion, we identified the detection of CTCs by flow cytometry or nested RT-PCR as potential prognostic tools in inoperable SCCHN. Detailed phenotyping of CTCs that can be done with the established flow cytometry method as opposed to the PCR-based techniques previously applied for CTC analysis in SCCHN might help in identifying novel therapeutic targets and increase our understanding of the molecular mechanisms responsible for treatment resistance in nonresectable SCCHN.
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